X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs SUN PHARMA - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES SUN PHARMA DIVIS LABORATORIES/
SUN PHARMA
 
P/E (TTM) x 18.0 15.2 118.1% View Chart
P/BV x 3.9 3.6 108.7% View Chart
Dividend Yield % 1.6 0.2 743.3%  

Financials

 DIVIS LABORATORIES   SUN PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-16
SUN PHARMA
Mar-16
DIVIS LABORATORIES/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs2,4841,201 206.8%   
Low Rs918706 130.0%   
Sales per share (Unadj.) Rs142.3117.5 121.1%  
Earnings per share (Unadj.) Rs41.919.6 213.7%  
Cash flow per share (Unadj.) Rs46.323.8 194.6%  
Dividends per share (Unadj.) Rs10.001.00 1,000.0%  
Dividend yield (eoy) %0.60.1 560.6%  
Book value per share (Unadj.) Rs161.5130.5 123.8%  
Shares outstanding (eoy) m265.472,406.60 11.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x12.08.1 147.3%   
Avg P/E ratio x40.648.7 83.5%  
P/CF ratio (eoy) x36.740.1 91.6%  
Price / Book Value ratio x10.57.3 144.1%  
Dividend payout %23.95.1 467.9%   
Avg Mkt Cap Rs m451,5252,294,813 19.7%   
No. of employees `0003.714.7 25.1%   
Total wages/salary Rs m3,64947,971 7.6%   
Avg. sales/employee Rs Th10,184.419,169.8 53.1%   
Avg. wages/employee Rs Th984.13,253.0 30.3%   
Avg. net profit/employee Rs Th2,998.53,197.9 93.8%   
INCOME DATA
Net Sales Rs m37,764282,697 13.4%  
Other income Rs m8486,170 13.8%   
Total revenues Rs m38,612288,867 13.4%   
Gross profit Rs m14,13883,239 17.0%  
Depreciation Rs m1,18210,135 11.7%   
Interest Rs m234,769 0.5%   
Profit before tax Rs m13,78174,505 18.5%   
Minority Interest Rs m0-11,126 0.0%   
Prior Period Items Rs m0-19 0.0%   
Extraordinary Inc (Exp) Rs m0-6,852 0.0%   
Tax Rs m2,6629,349 28.5%   
Profit after tax Rs m11,11947,159 23.6%  
Gross profit margin %37.429.4 127.1%  
Effective tax rate %19.312.5 154.0%   
Net profit margin %29.416.7 176.5%  
BALANCE SHEET DATA
Current assets Rs m30,947308,646 10.0%   
Current liabilities Rs m5,195132,477 3.9%   
Net working cap to sales %68.262.3 109.4%  
Current ratio x6.02.3 255.7%  
Inventory Days Days11783 140.8%  
Debtors Days Days8588 97.0%  
Net fixed assets Rs m17,027133,606 12.7%   
Share capital Rs m5312,407 22.1%   
"Free" reserves Rs m42,341266,909 15.9%   
Net worth Rs m42,877314,042 13.7%   
Long term debt Rs m531,167 0.0%   
Total assets Rs m49,684542,196 9.2%  
Interest coverage x595.016.6 3,579.4%   
Debt to equity ratio x00.1 0.1%  
Sales to assets ratio x0.80.5 145.8%   
Return on assets %22.49.6 234.1%  
Return on equity %25.915.0 172.7%  
Return on capital %32.217.8 181.4%  
Exports to sales %85.314.0 609.1%   
Imports to sales %22.93.1 729.4%   
Exports (fob) Rs m32,19839,572 81.4%   
Imports (cif) Rs m8,6548,882 97.4%   
Fx inflow Rs m32,27042,171 76.5%   
Fx outflow Rs m8,77521,583 40.7%   
Net fx Rs m23,49620,588 114.1%   
CASH FLOW
From Operations Rs m10,37967,694 15.3%  
From Investments Rs m-4,135-44,549 9.3%  
From Financial Activity Rs m-6,241-19,243 32.4%  
Net Cashflow Rs m33,902 0.1%  

Share Holding

Indian Promoters % 52.0 63.7 81.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 5.1 230.0%  
FIIs % 19.0 23.0 82.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 8.3 207.2%  
Shareholders   31,796 133,026 23.9%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   GSK PHARMA  JUBILANT LIFE SCIENCES  DISHMAN PHARMA  PIRAMAL ENTERPRISES  PLETHICO PHARMA  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens 200 Points Higher; Lupin & Axis Bank Top Gainers(09:30 am)

Majority of Asian stock indices are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.07%, while the Hang Seng is up 1.06%.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Aug 22, 2017 10:59 AM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - PANACEA BIOTECH COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS